Triple-negative breast cancer (TNBC), in which cells lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and the ERBB2 (also known as HER2) receptor, is the breast cancer subtype with the poorest outcome 1 . No targeted therapy is available against this subtype of cancer owing to a lack of validated molecular targets. We previously reported that signaling involving MYC-an essential, pleiotropic transcription factor that regulates the expression of hundreds of genes-is disproportionally higher in triple-negative (TN) tumors than in receptor-positive (RP) tumors 2 . Direct inhibition of the oncogenic transcriptional activity of MYC has been challenging to achieve 3 . Here, by conducting a shRNA screen targeting the kinome, we identified PIM1, a non-essential serine-threonine kinase, in a synthetic lethal interaction with MYC. PIM1 expression was higher in TN tumors than in RP tumors and was associated with poor prognosis in patients with hormone-and HER2-negative tumors. Small-molecule PIM kinase inhibitors halted the growth of human TN tumors with elevated MYC expression in patient-derived tumor xenograft (PDX) and MYCdriven transgenic mouse models of breast cancer by inhibiting the oncogenic transcriptional activity of MYC and restoring the function of the endogenous cell cycle inhibitor, p27. Our findings warrant clinical evaluation of PIM kinase inhibitors in patients with TN tumors that have elevated MYC expression.
Although de-regulated MYC signaling has been identified in a variety of human malignancies, no targeted therapy has been clinically established to treat solid tumors with elevated MYC expression. To date, small molecules designed to directly inhibit MYC transcriptional activity have not been successful in preclinical animal studies 3 . An alternative approach is indirect inhibition of oncogenic MYC activity by the targeting of druggable proteins that are essential for the viability of MYC-driven tumors but not nontumorigenic cells. This indirect treatment strategy has become known as a synthetic lethal approach 4 .
To identify new, readily druggable targets for the treatment of MYCoverexpressing TNBCs, we conducted a kinome-wide MYC synthetic lethal shRNA screen in non-immortalized human mammary epithelial cells 5 (HMECs) expressing a 4-hydroxytamoxifen (TAM)-activated MYC-Esr1 transgene 6 (hereafter referred to as HMEC-MYC-ER cells) (Fig. 1a) . MYC-dependent synthetic lethal screens using mammary epithelial cell systems have been previously reported 7, 8 ; however, to our knowledge, our screen is the first to use early-passage non-immortalized HMECs (obtained through breast reduction mammoplasty) that lack detectable genomic alterations 9 . This approach allows us to study the response of mammary epithelial cells to oncogenic MYC activation in a highly specific manner, independently of any potential confounding effects of in vitro cellular immortalization. Of 600 human kinases targeted by 2,000 individual shRNA clones, we identified nine kinases that were selectively required for the survival of HMEC-MYC-ER cells ( Fig. 1a and Supplementary Table 1 ). Kinase components of the NF-κB, mitogen (ERK and JNK), PI3K-AKT and WNT signaling pathways were identified, most of which had not been identified in prior synthetic lethal screens. Although any of these kinases could potentially serve as a druggable target for the treatment of MYC-overexpressing breast cancer, we decided to pursue further study of PIM1 kinase. Knockdown of PIM1 expression had the greatest efficacy among the kinase hits in causing cell death PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression 1 3 2 2 VOLUME 22 | NUMBER 11 | NOVEMBER 2016 nature medicine in MYC-activated cells, whereas it had minimal inhibitory effects on the growth of control cells ( Fig. 1a and Supplementary Table 1 ).
The dependence of MYC-activated HMECs on PIM1 expression for survival was confirmed by treatment of the cells with a pool of four PIM1-specific siRNAs ( Fig. 1b-d) , which resulted in a substantial amount of cell death in a MYC-dependent manner. PIM1 belongs to the PIM family of serine-threonine kinases, which consists of three proto-oncoproteins, PIM1, PIM2 and PIM3 (ref. 10) . Knockout mice lacking all three PIM kinases are fully viable and show only minor growth defects, which result in smaller body size 11 . This mild phenotype has raised the hope that PIM kinase inhibitors would induce less systemic toxicity than inhibitors of essential kinases. PIM kinases are thought to have weak tumorigenic capacity on their own 12 . However, PIM1 substantially enhances MYC-induced tumorigenesis in transgenic mouse models of lymphoma and prostate cancer 12, 13 . Accordingly, PIM kinase inhibition has been shown to decrease the growth of prostate cancer cells engineered to overexpress MYC and PIM1 (refs. 14,15). However, the efficacy of PIM inhibition as a MYC-synthetic-lethal therapeutic has not been stringently validated in preclinical animal models, particularly those for breast cancer. Notably, one of the other hits in our screen was BMX (also known as ETK) (Fig. 1a and Supplementary Table 1 ), which encodes a nonreceptor tyrosine kinase that physically interacts with PIM1 (ref. 16) , suggesting that multiple components of the PIM1 pathway may have a critical role in MYC-dependent breast tumor growth.
PIM kinase expression and function has been poorly described in human breast cancer. Thus, we first determined receptor-status-specific expression of PIM1 in primary tumor samples across four distinct publicly available clinical cohorts. In all of the cohorts examined, PIM1 mRNA expression was significantly elevated in TN tumors as compared to that in hormone receptor (HR)-positive but HER2-negative tumors, and in all but one cohort as compared to PIM1 mRNA expression in HER2-positive tumors (Fig. 2a) . Notably, a recent report showed that in the ER-responsive breast cancer cell line MCF7, PIM1 expression could be induced not only by ER activation with estrogen but also by depletion of estrogen receptor alpha (ERα) when the cells were cultured in the absence of estrogen 17 . Thus, although the precise mechanism by which ER signaling modulates PIM1 expression remains to be elucidated, loss of expression of HRs, such as ERα, during the process of primary tumor development may contribute to the upregulation of PIM1 expression that is observed in primary human TN tumors. Consistent with a prior observation that PIM1 expression is associated with higher-grade breast tumors 17 , we found that, for two of the three clinical cohorts that had long-term patient outcome data, increased PIM1 expression was associated with poor prognosis, as defined by either diminished recurrence-free or distant-metastasisfree survival, in patients with HR-negative tumors (Fig. 2b,c) .
We also examined receptor-status-specific expression and prognostic value of the other PIM kinase family members, PIM2 and PIM3. We found a tendency for PIM2 expression to be increased in TN tumors; however, the extent of this increase was not as consistent as that found for PIM1 (Supplementary Fig. 1a) , and neither was the prognostic value of PIM2 as consistent as that of PIM1 (Supplementary Fig. 1b,c) . Our analysis did not find an association of PIM3 expression with any specific receptor status and did not reveal prognostic value for PIM3 expression ( Supplementary Fig. 2) .
We next sought to determine whether a MYC-dependent transcriptional gene signature (hereafter referred to as MYC gene signature) and PIM1 expression are independently associated with survival across several clinical cohorts, using multivariate Cox proportionalhazard modeling (Fig. 2d) . In the HR-negative subset of the two largest clinical cohorts, increased PIM1 expression was associated with a significantly higher risk of recurrence, independently of a MYC gene signature. In the I-SPY1 data set, the smallest cohort, a MYC gene signature was significantly associated with worse outcome 2 independently of PIM1 expression (Fig. 2d) . Thus, although both MYC and PIM1 are overexpressed in TNBCs (Fig. 2a and ref. 2), and overexpression of each of these genes is associated with patient outcome, these associations are independent from one another. These findings indicate that the poor outcome associated with high levels of PIM1 expression across several data sets is independent of the presence of a MYC gene signature (Fig. 2d) .
To assess the feasibility of PIM1 inhibition as a therapy for TN tumors with elevated MYC expression, we treated a panel of breast cancer cell lines with a PIM1-specific siRNA and studied the effects on cell proliferation and cell death (Fig. 3a-f) . This panel included a nontumor cell line (HMEC) and ten breast cancer cell lines with varying degrees of MYC and PIM1 expression (Fig. 3a) . PIM1-specific siRNA treatment significantly decreased the proliferation of a number of breast cancer cell lines (Fig. 3b,c) and also induced appreciable amounts of cell death (Fig. 3e) . We asked whether a correlation exists between the sensitivity of the cell lines to PIM1 inhibition and protein levels of MYC and PIM1. As assessed by the relative sensitivity of the cell lines, the levels of MYC protein expression, and that of PIM1 to a lesser extent, significantly correlated with the sensitivity of the cell lines to PIM1 knockdown (Fig. 3d,f) . We also observed a correlation between MYC mRNA expression and sensitivity to PIM1 knockdown ( Supplementary Fig. 3 ), although this correlation was less significant than that for MYC protein expression. We noticed that the effect of PIM1 knockdown was rather shortlived in some of the cell lines ( Fig. 3b and Supplementary Fig. 4a) , consistent with prior observations that PIM1 mRNA and PIM1 PR status was not available for the pooled node-negative chemotherapy-naive data set; accordingly, ER − and ER + subsets were considered instead.
Hazard ratios for a 1 s.d. increase in PIM1 expression or MYC signature score are shown. P values were determined by the Wald test.
l e t t e r s 1 3 2 4 VOLUME 22 | NUMBER 11 | NOVEMBER 2016 nature medicine protein have short half-lives and that PIM kinases are highly regulated at both the transcriptional and post-translational levels to maintain higher protein expression in tumors 10 . We next asked whether PIM1 knockdown could influence expression of other PIM kinases, namely PIM2, whose expression was found to be increased in TN tumors in some of the clinical cohorts ( Supplementary Fig. 1a ). PIM1-specific siRNA treatment of MDA-MB-231 cells, which show high expression of both MYC and PIM1, resulted in an increase in PIM2 protein expression, whereas PIM2-specific siRNA treatment did not seem to activate a similar compensatory response with respect to PIM1 expression ( Supplementary Fig. 4a ). PIM2-specific siRNA treatment was as effective as PIM1-specific siRNA treatment in inhibiting cell proliferation of MDA-MB-231 cells, and it was more effective in inducing cell death ( Supplementary Fig. 4b,c) . These observations suggest that simultaneous inhibition of multiple PIM kinases may prove particularly efficacious in the treatment of breast tumors with elevated MYC and PIM1 expression. We next evaluated the effect of PIM kinase inhibition, using the pan-PIM kinase inhibitor SGI-1776 (ref. 18 ), on the in vivo growth of breast cancer cell lines that were injected subcutaneously as xenografts into immunocompromised mice. Tumors derived from the TN line MDA-MB-231 (high levels of MYC and PIM1) and the RP line T47D (low levels of MYC and medium levels of PIM1), which showed differential sensitivity to PIM1-specific siRNA in cell culture, were grown until they reached ~200 mm 3 in size. The tumor-bearing mice were then treated with 75 mg per kg body weight (mg/kg) SGI-1776 or vehicle control daily via oral gavage for 14 d. SGI-1776 treatment significantly reduced MDA-MB-231, but not T47D, xenograft tumor growth (Fig. 3g) .
For a more stringent preclinical assessment of the efficacy of PIM kinase inhibition in treating MYC-driven TN tumors, we took advantage of recently developed PDX mouse models of breast cancer 19 , which have varying expression levels of MYC and PIM1 (Fig. 3h) . The HCI-002 PDX, which was derived from a primary tumor collected before treatment of the patient with systemic chemotherapy, showed a poorly differentiated TN phenotype (Supplementary Table 2 ) 19 and had the highest level of MYC expression of the three PDX models tested in this study (Fig. 3h) . PDX tumors were orthotopically transplanted into the mammary gland of immunocompromised mice and were allowed to grow to a volume of 400-450 mm 3 before treatment was initiated with 75 mg/kg SGI-1776, 100 mg/kg NVP-LGB321 (a structurally distinct, newer generation pan-PIM kinase inhibitor from Novartis) 20 or vehicle control daily via oral gavage for 14 d. PIM447 (a compound structurally similar to NVP-LGB321; Novartis) 21 is currently being evaluated in multiple phase 1 and 2 trials for treatment of hematopoietic cancers. Vehicle-treated HCI-002 tumors rapidly reached the ethical end point of this study (Fig. 3i-k) . In contrast, SGI-1776 treatment markedly decreased tumor growth, whereas NVP-LGB321 treatment induced partial tumor regression (Fig. 3j,k) . PIM-inhibitor-treated tumors showed a significant decrease in the number of the proliferating (Ki67 + ) cells (Fig. 3l) and a modest increase in the number of apoptotic cells (as assessed by TUNEL staining) (Supplementary Fig. 5 ). To confirm that PIM inhibitor sensitivity in vivo was dependent on elevated MYC expression, we used two additional PDX tumor lines, HCI-004 and HCI-009. These PDX tumors were orthotopically transplanted into the mammary gland of immunocompromised mice and allowed to grow to a volume of 400-450 mm 3 before treatment was initiated with In d,f, each dot indicates a cell line, and the relative sensitivity of each cell line (y axis) refers to the ratio of the mean value of PIM1-specific siRNA-treated samples relative to the mean value of control-siRNA-treated samples. The experiments in c,e were independently repeated three times in triplicate. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test comparing the control-siRNA-treated group to each of the experimental groups. *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant. (g) In vivo growth of MDA-MB-231 (top) and T47D (bottom) xenograft tumors in nude mice that were treated with or without (control; treatment with diluent only) the smallmolecule PIM kinase inhibitor SGI-1776 (at 75 mg/kg via oral gavage, daily, for 2 weeks (MDA-MB-231, n = 6 mice per treatment group; T47D, n = 5 mice per treatment group). The percentage change in tumor volume was calculated for each animal. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test comparing the control-treated group to the SGI-1776-treated group. (h) Representative western blot analysis (n = 3) of PIM1 and MYC expression in a panel of previously reported patient-derived orthotopic breast tumor xenografts. PIM1 and MYC levels in nontumorigenic breast tissue were assessed in breast organoids derived from tissue collected through breast reduction mammoplasty. Numbers shown indicate the relative protein expression of MYC in these PDX tumors. Actin was used as a loading control. (i) Representative micrographs (n = 3 mice in each treatment group) of HCI-002 PDX tumors before (day 0) and after 2 weeks of treatment with SGI-1776 (75 mg/kg), or after control treatment with diluent (oral gavage, daily, for two weeks). Tumor chunks, approximately at 4~6 mm 3 in volume, were orthotopically transplanted into the cleared mammary fat pads of female NOD-SCID mice and allowed to reach ~450 mm 3 in volume before treatment was initiated. Red arrowheads indicate tumors. (j,k) The effects of PIM kinase inhibitors SGI-1776 (n = 6 mice in each treatment group) (j) and NVP-LGB321 (n = 7 mice in each treatment group) (k) on ethical end-point survival (left) and in vivo growth (right). Ethical end-point survival shows the fraction of surviving mice as mice were removed from the experiment after the size of their tumor reached the institutional limit of reaching or exceeding 2 cm in any one dimension. The percentage change in tumor volume was calculated for each animal. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test unless otherwise indicated. (Fig. 3h) , significantly attenuated tumor growth, but tumor growth was not completely inhibited (Fig. 3m) . The marked effect of drug treatment on the growth HCI-004 tumors that was observed during the course of treatment was maintained even after treatment was discontinued (Supplementary Fig. 6 ). In contrast, HCI-009 tumors, which showed a low level of MYC expression similar to that found in nontumor mammary tissue (Fig. 3h) , did not show significant sensitivity to NVP-LGB321 during the course of treatment (Fig. 3n) . 
PIM1
Actin siRNA: To confirm the finding that TN tumors with increased MYC expression are sensitive to PIM kinase inhibition, we examined the effects of PIM inhibition in a conditional transgenic mouse model of MYCdriven breast cancer (TetO-MMTV;TRE-MYC) 22 . In this model, tumor growth is dependent on doxycycline-induced MYC expression in mammary tissues, such that removal of doxycycline results in tumor regression (Fig. 3o) . TetO-MMTV;TRE-MYC tumors were orthotopically transplanted into the mammary gland of isogenic mice and allowed to grow to a volume of 400-500 mm 3 before treatment was initiated with 100 mg/kg NVP-LGB321 or vehicle control daily via oral gavage for 12 d. NVP-LGB321 treatment nearly abolished the ability of MMTV-MYC allograft tumors to grow (Fig. 3o) , as compared to control-treated tumor-bearing mice. These data provide genetic evidence that MYC-driven breast tumors require PIM kinase activity to maintain tumorigenesis.
To understand the mechanisms by which PIM inhibition abrogates the growth of MYC-overexpressing tumors in vivo, we examined whether PIM kinase targets are affected in HCI-002 tumors after the tumor-bearing mice were treated with the inhibitors. PIM kinases are known for their role in phosphorylating a number of target proteins, including MYC on Ser62 (which increases MYC transcriptional activity and its oncogenic potential 23, 24 ), the endogenous cyclin-dependent kinase (CDK) inhibitors p21 and p27 (which negatively controls their activities 25, 26 ), the CDK phosphatases Cdc25A and Cdc25C (which results in CDK activation 27, 28 ), the pro-apoptotic BCL2 family member BAD (which inhibits its function 29 ) and 4EBP1, a regulator of cap-dependent protein synthesis (which increases the level of protein synthesis 30 ). Among these PIM kinase substrates, we found that protein expression and/or phosphorylation status of MYC, p27 and BAD were most consistently and markedly altered in drug-treated PDX tumors ( Fig. 4a and Supplementary Fig. 7) . As compared to tumors from mice that were control-treated, tumors from mice that were treated with either of the PIM inhibitors showed marked reductions in total MYC expression and in the amount of Ser62-phosphorylated (pSer62) MYC (Fig. 4b) . Two weeks of drug treatment did not consistently alter the amount of Thr58 phosphorylation (red arrow, Fig. 4a) , which negatively affects MYC transcriptional activity 24, 31 . Notably, some of the tumors from vehicle-treated mice (i.e., 2-week control tumors) showed a marked decrease in Thr58 hyperphosphorylation during primary tumor progression (Fig. 4a) . These observations suggest that whereas MYC activity increases in control tumors, PIM inhibition results in an overall decrease in MYC activity. Consistent with this hypothesis, we found that expression of a bona-fide MYC transcriptional microRNA (miRNA) target, miR-18 (ref. 32) , was uniformly low in tumors from drug-treated mice as compared to those from vehicle-treated mice (Supplementary Fig. 8) . A similar trend was observed for other MYC-activated miRNAs, namely miR-19b and miR-20a (Supplementary Fig. 8) . These results are consistent with the observation that the expression of a number of MYC signature genes is altered following PIM kinase inhibitor treatment in sensitive TNBC cell lines 33 .
Consistent with a decrease in tumor cell proliferation, as measured by Ki67 staining (Fig. 3l) , PDX tumors from drug-treated mice showed significantly increased total p27 expression levels (Fig. 4a,c,d) , whereas protein expression levels of CDKs, CDC25A, CDC25B and p21 were not altered (Supplementary Fig. 7) . Regulation of p27 involves multiple steps of phosphorylation. Phosphorylation of p27 on Ser10 is required for its binding to the interphase CDKs that are bound to their respective cyclin partners, resulting in inhibition of CDK activity. Thr187 phosphorylation, which is mediated by CDKs, is required for proteasomal degradation of p27. Thr198 is phosphorylated by AKT and also by PIM, and Thr198 phosphorylation triggers p27 binding to 14-3-3 proteins, resulting in nuclear export of p27. Thus, whereas Ser10 phosphorylation of p27 results in its activation, Thr187 and Thr198 phosphorylation both result in the inhibition of p27 function. In addition, Ser10 phosphorylation is required for subsequent phosphorylation on Thr187 and Thr198 (refs. 26,34,35) . In PDX tumors from drug-treated mice, levels of Ser10 phosphorylation mirrored those of total p27 (Fig. 4a,c) , indicating that inhibition of PIM kinase activity does not interfere with Ser10 phosphorylation. Figure 4 The growth suppressive effects of PIM inhibition on TN tumors involve both loss of MYC function and gain of p27 function. (a) Western blot analysis for expression and phosphorylation status of the indicated PIM1 substrates in HCI-002 PDX tumors harvested before (day 0) and after 2 weeks of treatment with either SGI-1776 (75 mg/kg, daily) or NVP-LGB321 (100 mg/kg, daily), or with their respective diluents as controls. Tumors were harvested 24 h after the final drug treatment. Three tumor samples from three independent mice are shown for each time point and treatment condition. The day 0 samples shown are identical across the two columns; blot exposures were made independently and do not control for inter-blot variation in overall band intensity. The red arrow indicates the Thr58 hyperphosphorylated form of MYC. Actin was used as a loading control. (b) Total MYC protein expression (relative to actin levels; top) and levels of phosphorylated MYC at Ser62 (relative to total MYC; bottom) in HCI-002 PDX tumors after PIM inhibitor treatment. Three tumor samples from three independent mice are represented for each treatment group. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test. (c) Total p27 protein expression (normalized to actin levels; top) and levels of phosphorylated forms of p27 (normalized to total p27; bottom) in HCI-002 PDX tumors after PIM inhibitor treatment. Three tumor samples from three independent mice are represented in each treatment group. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test. (d) Representative confocal images for staining of nuclei (with DAPI, blue) and p27 (green) in HCI-002 PDX tumors from mice that were treated with diluent (control) or SGI-1776 for 2 weeks (top) and quantification of the effects of SGI-1776 and NVP-LGB321 on p27 nuclear accumulation (bottom) (n = 3 mice in each treatment group). The percentage of p27-positive cells per high-power field (40×) is shown. Five high-power fields were assessed from each of the three independent tumor samples per treatment group. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test. Scale bar, 100 µm. (e) Representative western blot analysis (n = 3) for p27 protein expression in HMECs and a panel of breast cancer cell lines. Actin was used as a loading control. (f) Representative western blot analysis (n = 3) for MYC and p27 protein expression in a panel of breast cancer cell lines at the indicated times after treatment with DMSO, SGI-1776 or NVP-LGB321. The cells were treated with the inhibitors at 10 µM, except for HCC1143 cells, which were treated with SGI-1776 at 5 µM due to an excessive amount of cell death using 10 µM. Actin was used as a loading control. (g) Representative immunofluorescence images of p27 nuclear accumulation in a panel of TNBC cell lines and quantification of p27 nuclear accumulation (graph) after treatment with NVP-LGB321 (10 µM) or DMSO for 48 h (n = 6 for each experimental condition per cell line). Cells were stained with DAPI (blue) and for p27 (green). The number of nuclear p27 + cells was counted in three high-power fields (20×) per sample/slide. Error bars represent means ± s.e.m. P values were calculated by two-tailed t-test. Scale bar, 100 µm. (h) The effects of MYC knockdown and p27 upregulation on the proliferation of a panel of TNBC cell lines. The indicated TN lines containing a tetracycline-regulated CDKN1B transgene (Tet-p27) were transfected with either a non-targeting control (CTL) or a MYC-specific siRNA and cultured for 24 h, and they were then treated with doxycycline (Dox) or control diluent for 48 h. Top, cell numbers relative to the CTL, −Dox group (n =3); bottom, MYC and p27 protein levels, with actin used as a loading control. Error bars represent means ± s.e.m. P values were calculated by Tukey's multiple comparison test. Actin was used as a loading control. (i) Schematic representation of the proposed mechanisms of PIM inhibitor action in MYC-driven TN tumors.
In contrast, the patterns of Thr187 and Thr198 phosphorylation did not follow that of total p27 (Fig. 4a,c) , as the amount of Thr187-or Thr198-phosphorylated p27 in tumors from drug-treated mice was similar to that observed in tumors from vehicle-treated mice and from mice before drug treatment (day 0 tumors). These observations suggest that in tumors from drug-treated mice, a large pool of CDKbound, Thr187-and Thr198-unphosphorylated p27 molecules may be trapped in the nucleus, which interferes with the CDK-p27 recycling mechanism that is essential for cell proliferation. Indeed, co-immunostaining for DAPI and p27 revealed significant nuclear accumulation of p27 in PDX tumors from drug-treated mice (Fig. 4d) .
The pro-apoptotic BCL2-family member BAD becomes activated after dephosphorylation at conserved sites including Ser112, which in turn results in activation of BAX and BAK, mediators of 1 3 2 8 VOLUME 22 | NUMBER 11 | NOVEMBER 2016 nature medicine mitochondria-dependent apoptotic cell death, leading to induction of apoptosis 29, 36 . Treatment of tumors with either of the PIM inhibitors resulted in a decreased level of Ser112 phosphorylation, with NVP-LGB321 having a greater effect than SGI-1776. (Fig. 4a) . This effect on BAD phosphorylation may, in part, account for the observation that HCI-002 tumors treated with NVP-LGB231 show partial tumor regression and an increase in the number of apoptotic cells (Fig. 3k and Supplementary Fig. 5 ).
We next asked whether the effects observed on MYC and p27 expression after treatment of PDX tumors with PIM inhibitors are also evident in tumor cell lines treated in vitro, by using a panel of breast cancer cell lines that show differential sensitivity to PIM inhibitors (Supplementary Fig. 9 ) and have varying endogenous protein expression levels of PIM1 (Fig. 3a) , MYC (Fig. 3a) and p27 (Fig. 4e) . In the absence of drug treatment, p27 protein expression was markedly lower in TN cell lines than in a nontumor cell line (HMEC) or in RP cell lines. (Fig. 4e) . Lower CDKN1B mRNA levels were also observed in TNBC samples than in HR-positive tumors from clinical data sets (Supplementary Fig. 10 ). PIM inhibitor treatment reduced MYC protein expression in the panel of cell lines examined (Fig. 4f) , and this effect seemed to be independent of their receptor status or their dependence on MYC for cell proliferation ( Supplementary  Fig. 11a-c) . PIM inhibition, however, did not substantially reduce MYC mRNA expression (Supplementary Fig. 12 ), suggesting that the reduction in MYC protein expression induced by PIM inhibition probably occurs via post-transcriptional mechanisms. In contrast, PIM inhibitor treatment upregulated p27 expression in TN cell lines that are dependent on MYC for cell proliferation ( Supplementary  Fig. 11a-c) but not in RP cell lines (Fig. 4f,g ). Similar effects on MYC expression were observed with PIM1 knockdown using a PIM1-specific siRNA (Supplementary Figs. 11a and 13) . Notably, the sensitivity of the panel of breast cancer cell lines to PIM1 inhibition was more strongly correlated with protein expression levels of MYC and PIM1 (positive correlation) than with baseline p27 protein expression (negative correlation) (Fig. 3c-f and Supplementary Fig. 14) . Finally, TN cell lines that are sensitive to PIM inhibitors showed an induction of nuclear p27 accumulation (Fig. 4g) , which was also seen in vivo after PIM inhibitor treatment of mice with PDX tumors (Fig. 4d) .
To test whether increased p27 expression alone is sufficient to inhibit TN cell proliferation, we studied the sensitivity of TN lines to increased p27 expression. We conditionally increased p27 expression in the presence or absence of siRNA-mediated MYC knockdown using a doxycycline-regulated approach (Fig. 4h) . In doing so, we attempted to achieve an extent of p27 upregulation similar to that observed in PIMinhibitor-treated PDX tumors in vivo (Fig. 4a) . Induction of p27 overexpression significantly diminished cell proliferation in all of the lines tested (Fig. 4h) , and induction of p27 overexpression together with MYC knockdown resulted in further growth inhibition (Fig. 4h) . Thus, the near-complete growth inhibition seen in PIM-inhibitor-treated PDX tumors is probably due to cumulative antiproliferative effects of diminished MYC activity and elevated p27 expression (Fig. 4i) .
Our observation that PIM inhibition results in diminished MYC activity in TN tumors, combined with the previous observation that PIM kinases are non-essential in mice 11 , makes PIM an attractive therapeutic target for breast cancer. Moreover, previous observations in numerous breast cancer clinical cohorts have associated diminished p27 expression with poor prognosis 37 , and we found that PIM inhibition results in increased levels of nuclear p27. A report by the Cancer Genome Atlas (TCGA) Breast Group indicates that the CDKN1B gene, which encodes p27, is neither deleted nor mutated in the vast majority of TN tumor samples 38 , supporting the potential use of PIM inhibition in restoring p27 expression and function in these aggressive tumors. In conclusion, our work identifies PIM1 kinase as a factor that is specifically upregulated in TNBC and is a potentially druggable target in tumors that show increased MYC expression.
METHODS
Methods and any associated references are available in the online version of the paper. Indirect immunofluorescence microscopy. For immunostaining of primary PDX tissues for Ki67 and p27 protein expression, paraffin-embedded tissue samples were sectioned, deparaffinized and rehydrated. Antigen retrieval was done using 10 mM sodium citrate, pH 6.0. Nonspecific binding sites were blocked with 5% normal goat serum. The blocked samples were incubated with primary antibodies against Ki67 (Abcam, ab833, 1:400) and p27 (BD Transduction Laboratories, 610241, 1:500) overnight at 4 °C. After washing, the samples were incubated for 1 h at room temperature with the fluorescently labeled secondary antibodies Alexa-Fluor-488-conjugated goat anti-mouseIgG (Invitrogen, A-11001, 1:500) or Alexa-Fluor-488-conjugated goat antirabbit-IgG (Invitrogen, A-11008, 1:500), respectively. The samples were then embedded in mounting medium containing DAPI (Dako), and the images were acquired using the Zeiss Axiovert 200M spinning disk confocal system equipped with Micro Manager software. The acquired images were processed using ImageJ (Fiji). To quantify the percentage of Ki67-and p27-positive cells per high-power field (40×), at least five images per sample were taken for each of three drug-treated and three control-treated samples. For each image, we determined the number of DAPI-positive nuclei using ImageJ, and the number of Ki67-or p27-positive cells was counted manually.
For immunostaining of the established breast cancer cell lines for p27 protein expression, the cells were fixed with 4% paraformaldehyde in 6-well plates, blocked with 3% normal goat serum and treated with the p27-specific primary antibody (BD Transduction Lab., 610241, 1:500) and with secondary antibody (Alexa-Fluor-488-conjugated goat anti-mouse-IgG, Invitrogen, A-11029, 1:500). Nuclear staining was done through the use of the mountant ProLong Gold antifade reagent with DAPI (Life Technologies). The images were acquired using the Zeiss Axioplan 2 epifluorescence imaging system equipped with the Micro Manager software.
Real-time quantitative PCR. Total RNA from the PDX tumor samples was extracted using the mirVana miRNA isolation kit (Ambion) according to the manufacturer's instructions. Real-time PCR was carried out using TaqMan probes (Applied Biosystems) specific for miR-18a, miR-19b and miR-20a, and the values were normalized relative to the expression of the small nucleolar RNA, C/D box 48 (SNORD48; also known as RNU48) endogenous control gene. siRNA experiments. Gene-specific pools of siRNAs were purchased from GE Dharmacon (siGENOME SMARTpool siRNA, M-003923-00-0005 for the PIM1-specific pool, M-005359-00-0005 for the PIM2-specific pool and M-005359-00-0005 for the MYC-specific pool), and siRNA transfection was performed using Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) via the reverse-transfection method, as previously described 2 . To sufficiently reduce PIM1 protein expression, particularly in the panel of triple-negative breast cancer cell lines, it was necessary to use the PIM1-spcific siRNA at the highest suggested dose (120-150 pmol per well in 6-well cell culture dishes). Even at these concentrations, we observed that some of the cell lines started to recover endogenous levels of PIM1 expression in less than 60 h post siRNA reversetransfection (for example, MDA-MB-231 cells in Fig. 3b and Supplementary   Fig. 4a ). PIM2-specific siRNA was used at 120 pmol per well in 6-well cell culture dishes. To knock down MYC expression in breast cancer cell lines, the MYC-spcific siRNA was used at 60 pmol per well in 6-well cell culture dishes. For control siRNAs, we used both Dharmacon siGENOME GAPD Control siRNA (D-001140-01-05) and siGENOME RISC-Free siRNA (D-001220-01-05); these two siRNAs caused similar and acceptable levels of cytotoxicity.
In vitro cell proliferation and cell death assays. Unless otherwise noted, cell proliferation and cell death were assessed by performing a flow-cytometrybased Guava ViaCount viability assay (Millipore). For the experiments shown in Figure 3e , Guava Nexin reagent (Millipore) was used to specifically determine the number of apoptotic and dead cells that were positive for annexin V and/or 7-AAD staining. For the experiments shown in Figure 4i , cell number was determined by counting the cells using the Countess Automated Cell Counter (Life Technologies) according to the manufacturer's instructions.
Transgenic breast cancer cell lines.
A doxycycline (tet)-regulated CDKN1B expression construct was generated by subcloning a full-length human CDKN1B cDNA (with a GCCACC Kozak sequence in front of the start codon) into the BamH1-EcoR1 sites of the multiple cloning site of pLVX-Tight-Puro lentiviral expression plasmid (Clontech). To produce recombinant lentiviral supernatants, 293FT cells were cotransfected with the ViraPower Lentiviral Packaging Mix (Life Technologies) and either pLVX-Tight-Puro-p27 or the transactivator construct pLVX-Tet-ON Advanced, using the Lipofectamine 2000 Transfection Reagent. Breast cancer cell lines were co-incubated with the resulting Tight-Puro-p27 supernatant and the Tet-ON Advanced supernatant, mixed at the ratio of 3:1, in the presence of polybrene at 6 µg/ml for 24 h. We found that the degree to which doxycycline (100 ng/ml) induced an increase in p27 protein expression was similar to the degree of p27 upregulation in PIM-inhibitor-treated PDX tumor tissues (for example, Fig. 4a,h) . Thus, for the experiments shown in Figure 4i , p27 upregulation was achieved by treating the established transgenic cell lines with doxycycline at 100 ng/ml. TUNEL staining. TUNEL staining was carried out on PDX tumor sections using the ApopTag Peroxidase In situ Apoptosis Detection Kit (Millipore), according to the manufacturer's instructions.
Statistical analyses.
All results are shown as mean ± s.e.m., unless otherwise indicated. Statistical analyses (two-tailed t-test, Pearson correlation, log-rank test and Tukey's multiple-comparison test) were performed using Prism 6 (version 6.0f) from GraphPad Software, Inc. and R (Version 3.1.0), taking into consideration the assumptions required for the respective tests. P < 0.05 was considered to indicate statistical significance throughout the study. All cell-based in vitro experiments were independently repeated three times in triplicate. No statistical method was used to pre-determine sample size throughout this study. For animal experiments, efforts were made to achieve the scientific goals of this study with the minimum number of animals. With respect to randomization, for animal experiments, tumor-bearing mice of similar tumor burden were equally divided into the control and experimental groups for subsequent drug treatment. For immunostaining (DAPI and p27) and TUNEL staining of PDX tumor samples, the scoring process was carried out in a blinded fashion. No experimental samples were excluded throughout this study, with the exception that animals that experienced unexpected, acute illness and/or injury were removed per the veterinarian's order.
Code availability. All custom computer code and data sets used for bioinformatics analyses, as outlined below, are freely available for download and/or use on Github at https://github.com/snjvb/pim_kinase. The raw data and processing routines are included for the following data sets (directory names for the respective data sets are indicated in parentheses): TCGA breast invasive carcinoma data set (TCGA_BRCA_exp_HiSeqV2-2014-08-28), chemotherapynaive data set (YauGeneExp-2011-11-11), I-SPY1 data set (ispy1_082814) and pooled neoadjuvant-chemotherapy-treated data set (gse25066_091114). The core analysis pipeline, written in the R programming language, is included in the file 'pim_analysis.r' . Additional code for multivariate analysis of MYC signature and PIM1 expression are available upon request.
